Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance

Campagna, Roberto; Pozzi, Valentina; Giorgini, Sara; Morichetti, Doriana; Goteri, Gaia; Serritelli, Emma Nicol; Emanuelli, Monica

doi:10.1007/s13577-023-00892-9

Cited by 17 publications

(18 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Paraoxonase-2 (PON2) is an enzyme which counteracts oxidative stress by decreasing the generation of reactive oxygen species (ROS). Interestingly, this enzyme has been found to be upregulated in malignant cells and to be associated with aggressiveness and chemoresistance [ 46 ]. An in-vitro study examining BC specimens demonstrated TNBC cells to be characterized by an overexpression of this enzyme in comparison to healthy cells.…”

Section: Resultsmentioning

confidence: 99%

“…An in-vitro study examining BC specimens demonstrated TNBC cells to be characterized by an overexpression of this enzyme in comparison to healthy cells. Additionally, PON2 knockdown led to a notable decrease in cell proliferation compared to control ( p = 0.039 at the 48-h timepoint and p = 0.022 at the 72-h timepoint), suggesting it as a potential effective therapeutic target for TNBC [ 46 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches

Pastena,

Perera,

Martinino

et al. 2024

IJMS

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, marked by poor outcomes and dismal prognosis. Due to the absence of targetable receptors, chemotherapy still represents the main therapeutic option. Therefore, current research is now focusing on understanding the specific molecular pathways implicated in TNBC, in order to identify novel biomarker signatures and develop targeted therapies able to improve its clinical management. With the aim of identifying novel molecular features characterizing TNBC, elucidating the mechanisms by which these molecular biomarkers are implicated in the tumor development and progression, and assessing the impact on cancerous cells following their inhibition or modulation, we conducted a literature search from the earliest works to December 2023 on PubMed, Scopus, and Web Of Science. A total of 146 studies were selected. The results obtained demonstrated that TNBC is characterized by a heterogeneous molecular profile. Several biomarkers have proven not only to be characteristic of TNBC but also to serve as potential effective therapeutic targets, holding the promise of a new era of personalized treatments able to improve its prognosis. The pre-clinical findings that have emerged from our systematic review set the stage for further investigation in forthcoming clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches

Pastena,

Perera,

Martinino

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Many chemotherapeutic agents (e.g., platinum-derived drugs) rely on the induction of oxidative stress, which leads to cell damage and cancer cell death [ 95 , 96 ]. For this reason, targeting redox regulation in cancer cells is a promising strategy to overcome drug resistance.…”

Section: Intracellular Modulators Of Slc7a11 In Ovarian Cancermentioning

confidence: 99%

Role of SLC7A11/xCT in Ovarian Cancer

Fantone,

Piani,

Olivieri

et al. 2024

IJMS

View full text Add to dashboard Cite

Ovarian cancer is one of the most dangerous gynecologic cancers worldwide and has a high fatality rate due to diagnosis at an advanced stage of the disease as well as a high recurrence rate due to the occurrence of chemotherapy resistance. In fact, chemoresistance weakens the therapeutic effects, worsening the outcome of this pathology. Solute Carrier Family 7 Member 11 (SLC7A11, also known as xCT) is the functional subunit of the Xc− system, an anionic L-cystine/L-glutamate antiporter expressed on the cell surface. SLC7A11 expression is significantly upregulated in several types of cancers in which it can inhibit ferroptosis and favor cancer cell proliferation, invasion and chemoresistance. SLC7A11 expression is also increased in ovarian cancer tissues, suggesting a possible role of this protein as a therapeutic target. In this review, we provide an overview of the current literature regarding the role of SLC7A11 in ovarian cancer to provide new insights on SLC7A11 modulation and evaluate the potential role of SLC7A11 as a therapeutic target.

show abstract

“…The evaluation of the expression of specific biomarkers led to important results for predicting the occurrence/progression of several cancerous [4][5][6][7][8][9][10] and noncancerous [11][12][13] diseases, as well as identifying novel therapeutic targets [14][15][16][17][18][19].…”

mentioning

confidence: 99%